MHRA Largest Seizure of Unlicensed Weight Loss Medicines
Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.
2 SOPs may need review
InSphero AG has announced the acquisition of PhenoVista Biosciences, a CRO focused on high-content imaging and phenotypic assay technologies. PV and quality teams may need to reassess vendor governance and documentation continuity for safety-related testing services.
This update requires triage for Risk Management, Vendor Oversight, Inspection Readiness; confirm local obligations and document follow-up actions.
QPPV
Immediate triage (within 1 business day), then weekly review until closure.
Primary-source confirmation recommended before operational implementation.
InSphero AG has announced the acquisition of PhenoVista Biosciences, a CRO focused on high-content imaging and phenotypic assay technologies. PV and quality teams may need to reassess vendor governance and documentation continuity for safety-related testing services.
Potential impact spans Risk Management, Vendor Oversight, Inspection Readiness, Label Governance, so QPPV oversight is needed to maintain compliance readiness and evidence traceability.
This update requires triage for Risk Management, Vendor Oversight, Inspection Readiness; confirm local obligations and document follow-up actions.
Review adverse event reports for potential links to counterfeit weight loss medicines; check product supply chain for unlicensed sources.
2 SOPs may need review
Review product inventory for Tawon Liar; report any adverse events to FDA MedWatch; consider adding product to signal monitoring list; ensure labeling compliance checks for similar products.
2 SOPs may need review
Immediately quarantine and return unused MonaTherm probes from affected lots; review patient records for potential exposure and adverse events.
2 SOPs may need review
Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.
2 SOPs may need review